Lipid management in Type 2 diabetes: the case for combination therapy?

Author： Saely Christoph H   Drexel Veronika   Vonbank Alexander   Drexel Heinz  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.8, Iss.2, 2011-03, pp. : 129-141

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Xultophy: combination therapy for the treatment of type 2 diabetes

By  

PRESCRIBER, Vol. 26, Iss. 17, 2015-09 ,pp. : 32-34

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lipid lowering therapy in type 2 diabetes

By Föger Bernhard  

Wiener Medizinische Wochenschrift, Vol. 161, Iss. 11-12, 2011-06 ,pp. : 289-296

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

By Schwartz Stanley  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3009-3022

Informa Healthcare

Access to resources Recommend Favorite

Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 497-507

John Wiley & Sons Inc

Access to resources Recommend Favorite

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

By Pandya Bhavik J.   Bron Morgan   McCall Therese   Yu Andrew P.   Chen Kristina S.   Mattson Miles E.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 189-195

Informa Healthcare

Access to resources Recommend Favorite